echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical World News > Indian amine price, side effects, dosage description

    Indian amine price, side effects, dosage description

    • Last Update: 2020-05-18
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    The original drug of Rinnamine (Rui Fumei) is developed by The New Base Pharmaceutical Company of the United States mainly for the treatment of patients with multiple myeloma, myeloma hyperplasia abnormality, and autoimmune diseasesIt was approved by the U.SFDA in December 2005 to treat bone marrow hyperplasia syndrometo That's where the patient also has a patient translation for Reliduamine, Rui Fumei is its Chinese commodity nameStudies have shown that the amine can inhibit the formation of tumor blood vessels, stimulate the production of T lymphocytes and directly inhibit the role of tumor cellsTherefore, the amine can make tumor cells can not get nutrition and "starved to death", while reducing the tumor cells through the blood transfer to other parts of the situation, but also can improve the immune system, induce tumor cells apoptosisin addition to the role of that degree amine, the majority of patients are most concerned about the price of that degree amine is how much a box, domestic imports of that degree amine has 10mg and 25mg two specifications, domestic imports of the amount of 25mg x 21 pieces of health insurance after the price is about 3 or about a box, which is more expensive for many familiesHowever, India can produce generic drugs without the restrictions of patent law, and the Indian generic version of The Aphorite currently has four sizes: 5mg, 10mg, 15mg, 20mg, 25mgIndia's imitation version is less than one-tenth of the price in the country, and is relatively lowmultiple myeloma: Tonala is usually combined with dexamethasone, the recommended starting dose is 25 mg, every 28 days for a cycle, the first 21 days of oral time once a day 25 mg, after 7 days do not take that degree amineThe recommended dose of dexamethasone is 40 mg, with oral dexamethasone at the 1st, 8th, 15th and 22nd days of the 28-day treatment cyclebone marrow abnormality syndrome: The recommended starting dose is once a day, 10 mg at a timeUsage: Take warm water orally once, and drink a large cup of warm water while taking the medicineset of cell lymphoma: to nalaa needs to be used in combination with meloviratrites, a drug cycle is 28 days, the first 21 days of the dose is 25 mg once a day, the next 7 days do not take the drugthe side effects of nadota in different indications have a little difference, but is much the same, the main side effects are neutropeny cell reduction, platelet reduction, other adverse reactions including diarrhea, itching, rash, fatigue, constipation, nausea and vomiting, nasopharyngitis, joint pain, cough, headache, etc., such as other targeted drugs, to that degree of amine side effects can be alleviated by taking the method of disease
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.